drugset / Trial / NCT00358202

Cefepime vs. Ceftriaxone to Treat Nursing Home-Acquired Pneumonia

NCT00358202

Phase 4 Completed 69 enrolled CPL Associates Elan Pharmaceuticals · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

Randomized trial of nursing home residents with pneumonia to assess if intramuscular cefepime is a safe, efficacious, and cost-effective alternative to once daily intramuscular ceftriaxone for the treatment of elderly nursing home residents who develop pneumonia and do not require hospitalization.

Timeline

Start
2002-03
Primary completion
Completion
2006-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cefepime Small molecule 1 g Intramuscular
Comparator Ceftriaxone Other / unclassified 1 g Intramuscular

Indications